IL6 and Parkinson disease: In a rotenone-induced model of Parkinson’s disease (PD), TNF-α, IL-1β, IL-6 and macrophage inflammatory protein-1 beta (MIP-1b) along with α-synuclein were shown to be significantly reduced in hippocampus, substantia nigra, and striatum region and slight changes in cortex and brain stem region of animals with oral supplementation of (40 mg/kg body weight/for 4 weeks) BM.